Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to
evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) 80 mg s.c. QM
compared with placebo s.c. QM in US Black/African American and Hispanic participants with
established ASCVD and elevated levels of Lp(a) who are treated for cardiovascular (CV)
risk factors according to local practice/guidelines for the reduction of cardiovascular
risk. CTQJ230A12303 is a randomized, double-blind, placebo-controlled, multi-center, Phase IIIb
study to evaluate the efficacy ( measured by reduction of the Lp(a) levels) and safety of
pelacarsen (TQJ230) 80mg s.c. QM compared to placebo in US Black/African American and US
Hispanic participants, with established atherosclerotic cardiovascular disease (ASCVD) as
evidenced by history of coronary heart disease, cerebrovascular disease or symptomatic
peripheral artery disease (PAD) and elevated levels of Lp(a).

The study will consist of a screening period of approximately 30 days, followed by a
Guideline recommended SoC implementation period of approximately 30 days, if required,
and a doubleblind treatment period of 12 months. There will be a post-treatment follow-up
period of 16 weeks.